---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344580"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2026-08-11T20:05:15+00:00"
generated_at: "2026-08-11T20:06:17.889004+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports Q2 2026 operating loss of $8.4M; cash $18.1M funds into Q1 2027

## Summary
- Cash, equivalents and marketable securities $18.1M as of Jun 30, 2026; expected to fund operations into 1Q 2027.
- Collaboration revenue $5K vs $1.8M in Q2 2025; R&D expenses $5.1M vs $7.5M; G&A $2.4M vs $3.5M.
- Loss from operations $8.4M in Q2 2026 vs $9.2M in Q2 2025, driven by restructuring-related cost reductions.
- BDC-4182 Phase 1/2 in gastric/GEJ cancer ongoing; Cohort 4 dosing at 4.0 mg/kg; initial data expected with 3Q 2026 results.
- CEO Willie Quinn cites well-tolerated profile and activity consistent with immune-stimulating mechanism for BDC-4182.

## SEC filing metadata
- accession: 0001193125-26-344580
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2026-08-11T20:05:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/0001193125-26-344580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344580
- JSON: https://secwatch.observer/filing/0001193125-26-344580.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.